LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Listă Acțiuni・Quanterix Corp

Quanterix Corp

Închisă

SectorSănătate

2.72 -17.82

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

2.56

Maxim

3.29

Indicatori cheie
By Trading Economics
Venit	10M -23M
Vânzări	3.7M 44M
Marjă de profit	-52.712
Angajați	450
EBITDA	15M -17M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+21.58% upside

Statistici piață
By TradingEconomics
Capitalizare de piață	-137M 159M
Deschiderea anterioară	20.54
Închiderea anterioară	2.72

Sentimentul știrilor

By Acuity

62%

38%

303 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

5.34 / 6.015 Suport & Rezistență

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 mai 2026, 23:58 UTC

Câștiguri

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mai 2026, 22:57 UTC

Câștiguri

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mai 2026, 23:52 UTC

Câștiguri

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mai 2026, 23:11 UTC

Câștiguri

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mai 2026, 23:06 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mai 2026, 23:05 UTC

Câștiguri

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mai 2026, 23:04 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mai 2026, 23:03 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mai 2026, 23:03 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mai 2026, 23:02 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mai 2026, 22:42 UTC

Câștiguri

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mai 2026, 22:33 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mai 2026, 22:32 UTC

Câștiguri

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mai 2026, 22:31 UTC

Câștiguri

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mai 2026, 22:31 UTC

Câștiguri

Macquarie: 68% of FY Income From International >MQG.AU

7 mai 2026, 22:30 UTC

Câștiguri

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mai 2026, 22:30 UTC

Câștiguri

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mai 2026, 22:29 UTC

Câștiguri

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mai 2026, 22:28 UTC

Câștiguri

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mai 2026, 22:28 UTC

Câștiguri

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mai 2026, 22:27 UTC

Câștiguri

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mai 2026, 22:27 UTC

Câștiguri

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mai 2026, 22:26 UTC

Câștiguri

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mai 2026, 22:25 UTC

Câștiguri

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

21.58% sus

Prognoză pe 12 luni

Medie 4 USD 21.58%

Maxim 4 USD

Minim 4 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Quanterix Corp - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

303 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.